Flexible friend: Sanofi talks capacity benefits of Lonza JV

By Flora Southey contact

- Last updated on GMT

Sharing a facility with a CMO gives Sanofi the flexibility to adjust biomanufacturing capacity according to its needs, says its SVP for biologics.

Mergers, collaborations and partnerships are key components of Sanofi’s biologics strategy, said senior vice president and global head of Sanofi’s biologics platform Brendan O’Callaghan.

“Sanofi is transforming from being a predominantly small molecule-focused firm, to biologics based,” ​Callaghan told delegates at the BioPharma Ambition Conference last month.

As part of this, the French drugmaker announced plans​ to construct a large-scale mammalian cell culture manufacturing site in Visp, Switzerland, in February last year in a partnership with contract manufacturing organisation (CMO) Lonza.

O’Callaghan told delegates Sanofi is sharing the capital investment with the CMO, along with the plant utilisation, allowing the flexibility to manufacture biologic products, precise volumes of which can be difficult to forecast.

“If we don’t need it, Lonza being a CMO can market that capacity on the open market.”

Conversely, if Sanofi requires additional capacity, it will work with Lonza to make use of any excess they may have – or indeed work with them to expand the modular facility, and add additional capacity at a small, incremental cost.

The facility is expected to be completed by 2020.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more